The space economy is notoriously unforgiving of broken promises, and few stocks prove that point more painfully right now than Rocket Lab USA. Shares closed at $67.35 on Thursday, shedding 37.63% over the past month and sitting 55.40% below the May record high of $151. The decline is not the product of any single crisis but rather an accumulation of pressures — an $8 billion acquisition that spooks shareholders, an insider sale that landed at exactly the wrong moment, and a next-generation rocket that has already blown past its original launch date.
That the stock still shows a 31.21% gain over the past twelve months only underscores the volatility. This is a name that ran too hot, too fast, and is now paying the price as the market recalibrates its tolerance for execution risk.
The weight of the Iridium deal
The steepest headwind is Rocket Lab’s own making. Late June brought confirmation that the company would acquire satellite operator Iridium Communications for roughly $8 billion, financed through a mix of stock and cash. Existing shareholders immediately worried about dilution, and those fears have not eased despite the subsequent sell-off. The company retains a market capitalisation of around €41.86 billion, but the acquisition’s structure leaves open the question of how much equity will be issued.
Compounding that anxiety was a mandatory disclosure showing that CEO Peter Beck sold shares on March 27, 2026, under a pre-arranged 10b5-1 trading plan. Such programmes are routine, set well in advance, and carry no directional signal. Yet in a market already on edge, the news fed the narrative of insiders heading for the exit.
The selling pressure intensified mid-week when Piper Sandler analyst Alexander Potter initiated coverage with a neutral rating and an $83 price target. The cautious stamp of approval landed on a stock that was already searching for a floor. Some market watchers also attribute part of the slide to profit-taking linked to the SpaceX IPO — a sector-wide phenomenon rather than a Rocket Lab-specific issue.
A technical breakdown
The chart tells a story of mechanical overextension. Rocket Lab shares now trade 37.40% below their 50-day moving average and 13.80% below the 200-day line. The relative strength index has plunged to 29.8, deep in oversold territory, while the annualised 30-day volatility clocked in at nearly 98%. That level of turbulence is not typical of an industrial aerospace stock; it looks more like a highly leveraged options bet.
Oversold readings often produce sharp reversals, but they offer no guarantee of a floor. In this case, the stock’s extreme moves reflect what happens when a high-multiple growth name confronts both a dilutive deal and a delayed rocket programme simultaneously.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
Neutron: the variable no one can price
Underneath the noise lies the single factor that will determine whether this sell-off is a healthy correction or the beginning of something worse: the Neutron rocket. The partially reusable medium-lift vehicle was originally slated for a late-2025 debut, then pushed to the first half of 2026. In January, a main-stage fuel tank ruptured during testing, delaying the inaugural flight further — now set for the fourth quarter of 2026.
Rocket Lab insists the timeline holds. There has been one genuine technical milestone: the Archimedes engine that powers Neutron’s second stage recently completed a full-duration burn test. But since January, the company has offered few public updates on the hardware’s status. That gap between commercial momentum and unproven engineering is exactly what makes the stock prone to such violent swings.
The backlog provides some solace. Rocket Lab carries an order book worth more than $2.2 billion, including a five-flight dedicated Neutron contract and another multi-mission agreement covering five Neutron and three Electron launches through 2029. First-quarter 2026 results beat internal guidance, with record revenue and a growing pipeline. Yet none of those orders can be converted into cash flow until Neutron actually flies.
The prize beyond the launch
A successful maiden flight would open the door to the US National Security Space Launch programme, which could allocate up to $5.6 billion in contracts through 2029. Rocket Lab is already a qualified bidder for the Lane 1 category, but it cannot win individual missions until Neutron proves its flightworthiness. The company’s ability to compete for government and large commercial constellations hinges entirely on that first lift-off.
If Neutron flies on schedule in Q4 2026, the path to revenue from the backlog becomes clear, and the NSSL opportunity becomes real. If the launch slips again or fails, the consequences compound. The planned $8 billion Iridium acquisition is scheduled to close around mid-2027. A failed or further-delayed Neutron would make refinancing the deal far more difficult, likely forcing deeper dilution or a cash crunch. SpaceX’s 165 launches in 2025 stand as a reminder that the competitive landscape is dominated by a player with proven hardware and relentless cadence.
The binary outlook
With an RSI near 30 and the stock trading well below both its major moving averages, Rocket Lab occupies a technically stretched zone. Such zones can produce violent snap-backs in either direction. Oversold does not mean safe.
For now, the market has stopped giving management the benefit of the doubt. Until Neutron stands on the launch pad and the Iridium financing is clarified, extreme swings are not an anomaly — they are the new baseline. The next concrete catalyst for investors is the fourth-quarter 2026 target date, and beyond that, the outcome of the flight itself. Everything else is noise.
Ad
Rocket Lab USA Stock: Buy or Sell?! New Rocket Lab USA Analysis from July 17 delivers the answer:
The latest Rocket Lab USA figures speak for themselves: Urgent action needed for Rocket Lab USA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 17.
Rocket Lab USA: Buy or sell? Read more here...
